Antiviral activity of NMSO3 against adenovirus in vitro

被引:27
作者
Kaneko, H
Kato, K
Mori, S
Shigeta, S
机构
[1] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima 9601295, Japan
[2] Fukushima Med Univ, Sch Med, Dept Microbiol, Fukushima 9601295, Japan
关键词
adenovirus; anti-adenovirus; NMSO3; adsorption inhibitor; MTT method;
D O I
10.1016/S0166-3542(01)00167-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
NMSO3, a sulfated sialyl lipid, was evaluated for its efficacy against adenovirus (AdV) in vitro. The median effective concentration (50% effective concentration, EC50) of NMSO3 against replication of AdV type 2 (AdV2), type 4 (AdV4), type 8 (AdV8) and type 37 (AdV37) was 0.21-0.71 mug/ml in HEp-2 cells and 1.01-1.41 mug/ml in MKN-28 cells. The EC50 values of NMSO3 were lower than those of HPMPC and ddC, which were also evaluated. NMSO3 exhibited minimal cytotoxicity against HEp-2 cells and MKN-28 cells, both for which the median cytotoxic, concentration (50% cytotoxic concentration, CC50) was more than 1000 mug/ml. NMSO3 was the most potent and selective anti-AdV compound of those examined. NMSO3 inhibited AdV infection of HEp-2 cells only when present during the virus adsorption period. A virus binding assay using radiolabeled AdV4 revealed that NMSO3 inhibited viral binding to the HEp-2 cells. NMSO3 itself bound to the virus particles, but not to the HEp-2 cell membrane. Thus, the mechanism of anti-AdV activity by NMSO3 involves inhibition of virus adsorption to cells by NMSO3 binding to viral particles. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:281 / 288
页数:8
相关论文
共 30 条
[21]   Application of a gastric cancer cell line (MKN-28) for anti-adenovirus screening using the MTT method [J].
Kodama, E ;
Shigeta, S ;
Suzuki, T ;
DeClercq, E .
ANTIVIRAL RESEARCH, 1996, 31 (03) :159-164
[22]   Inhibitory activity of 3'-fluoro-2' deoxythymidine and related nucleoside analogues against adenoviruses in vitro [J].
Mentel, R ;
Kinder, M ;
Wegner, U ;
vonJantaLipinski, M ;
Matthes, E .
ANTIVIRAL RESEARCH, 1997, 34 (03) :113-119
[23]   Evaluation of the efficacy of 2′,3′-dideoxycytidine against adenovirus infection in a mouse pneumonia model [J].
Mentel, R ;
Wegner, U .
ANTIVIRAL RESEARCH, 2000, 47 (02) :79-87
[24]   LONG-TERM INHIBITION OF HUMAN T-LYMPHOTROPIC VIRUS TYPE-III LYMPHADENOPATHY-ASSOCIATED VIRUS (HUMAN-IMMUNODEFICIENCY-VIRUS) DNA-SYNTHESIS AND RNA EXPRESSION IN T-CELLS PROTECTED BY 2',3'-DIDEOXYNUCLEOSIDES INVITRO [J].
MITSUYA, H ;
JARRETT, RF ;
MATSUKURA, M ;
VERONESE, FD ;
DEVICO, AL ;
SARNGADHARAN, MG ;
JOHNS, DG ;
REITZ, MS ;
BRODER, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (07) :2033-2037
[25]  
NEYTS J, 1990, VIROLOGY, V3, P85
[26]  
Romanowski EG, 2000, INVEST OPHTH VIS SCI, V41, P460
[27]   Recent progress in antiviral chemotherapy for respiratory syncytial virus infections [J].
Shigeta, S .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (02) :221-235
[28]  
VONOOSTRUM J, 1985, J VIROL, V56, P439
[29]  
Wadell G, 1980, Ann N Y Acad Sci, V354, P16, DOI 10.1111/j.1749-6632.1980.tb27955.x
[30]   ADENOVIRUS PNEUMONIA WITH SEVERE SEQUELAE IN AN IMMUNOCOMPETENT ADULT [J].
ZARRAGA, AL ;
KERNS, FT ;
KITCHEN, LW .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (04) :712-713